menu
    • menu
    [{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Sciences Ireland Unlimited","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CIN-109","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma & Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma & Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma & Perceptive Advisors"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"CIN-109","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","graph1":"Technology","graph2":"Approved","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CinRx Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CinRx Pharma

    Menu

    CinRx Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIN-110

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CinFina Pharma Begins Phase 1 MAD Trial of CIN-110 for Obesity

                            Details : CIN-110 is a potent and highly selective large molecule peptide and a PYY3-36 analog, which is currently under development for the treatment of Obesity.

                            Brand Name : CIN-110

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 30, 2024

                            Lead Product(s) : CIN-110

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIN-109

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $176.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CinRx Pharma Announces Additional $73 Million Financing

                            Details : The financing aims to support the CinRx to focus on the clinical development of CIN-109, which is being evaluated in the early-stage clinical trial studies to treat obesity.

                            Brand Name : CIN-109

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : CIN-109

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $176.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : CinRx Pharma

                            Deal Size : $59.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            CinDome Pharma Announces $40 Million Series B Extension

                            Details : The financing aims to support the continued development of CIN-102 (deudomperidone) for the treatment of chronic gastroparesis, including preparation for registrational trials.

                            Brand Name : CIN-102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 16, 2024

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : CinRx Pharma

                            Deal Size : $59.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIN-110

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CinFina Announces FDA Clearance and First Doses in Phase 1 Trial of CIN-110

                            Details : CIN-110 is a potent and highly selective large molecule peptide and a PYY3-36 analog, which is currently under development for the treatment of Obesity.

                            Brand Name : CIN-110

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : CIN-110

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : CinRx Pharma & Perceptive Advisors

                            Deal Size : $19.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for th...

                            Details : The net proceeds will be used to develop CinDome Pharma’s Phase 2 envision3D study of CIN-102 (deudomperidone), a new chemical entity based upon deuteration and novel formulation of domperidone in patients with diabetic gastroparesis.

                            Brand Name : CIN-102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 27, 2023

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : CinRx Pharma & Perceptive Advisors

                            Deal Size : $19.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for th...

                            Details : CIN-102 (deudomperidone) is a new chemical entity based upon deuteration and novel formulation of domperidone (DA2-receptor antagonist), a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States.

                            Brand Name : CIN-102

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 27, 2023

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIN-109

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Janssen Sciences Ireland Unlimited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            CinFina Pharma In-Licenses Obesity Portfolio

                            Details : Under the agreement CinFina will be responsible for development, manufacturing and commercialization of CIN-109, with a multiple ascending dose Phase 1 clinical study, and following dose selection, will commence a Phase 2 study in overweight and obese ad...

                            Brand Name : CIN-109

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 22, 2021

                            Lead Product(s) : CIN-109

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Janssen Sciences Ireland Unlimited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth